Lv7
3870 积分 2021-02-08 加入
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
5天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
5天前
已完结
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts
26天前
已完结
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
1个月前
已完结
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies
2个月前
已完结
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival
2个月前
已完结
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
3个月前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
5个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
7个月前
已完结
Precision Oncology: 2025 in Review
7个月前
已完结
皖公网安备34019202002308
